Market Overview:
The global CXCL8 market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing demand for chemokine proteins for research and development purposes, rising prevalence of chronic diseases, and growing investments by biopharmaceutical companies in R&D activities. However, the high cost of production and lack of standardization are some factors that could restrain the growth of this market. Based on type, the global CXCL8 market is segmented into above 90%, above 95%, above 99%, and others. The majority share in this segment is held by products with an over 90% purity level. This is mainly due to their high efficiency in various applications such as biopharmaceutical companies, hospitals, bioscience research institutions, and others. Based on application, the global CXCL8 market is divided into four segments: biopharmaceutical companies; hospitals; bioscience research institutions; and others (including contract manufacturing organizations [CMOs], CROs).
 Industry Outlook.svg)
Product Definition:
CXCL8 is a chemokine protein that is produced by immune cells and recruits other immune cells to the site of infection or injury. It plays an important role in the inflammatory response and helps to coordinate the movement of white blood cells to where they are needed.
Above 90%:
Chemokine (CK) family is a group of small cytokines that regulate the immune response and inflammation. Chemokines are chemoattractants for leukocytes which include white blood cells, platelets, and fibroblasts. The CXCL8 protein is produced by activated T cells in response to antigen stimulation.
Above 95%:
Chemokine (CXCL8) is a type of cytokine, which is involved in the inflammatory response. The main function of chemokines is to attract and recruit immune cells from the blood. Chemokines are also known as interleukins because they belong to the same family as interleukin-1, -2, -3, and -4.
Application Insights:
The biopharmaceutical companies segment held the largest share of the global CXCL8 market in 2017. This is attributed to extensive R&D oncology and infectious diseases that use these proteins as a biomarker for diagnosis. The Hospitals segment is expected to register the fastest growth over the forecast period owing to increasing prevalence of chronic conditions, such as heart disease, cancer and diabetes mellitus across all regions.
CXCL8 has been found useful in treating several chronic diseases due to its ability to regulate inflammatory mediators like cytokines, chemokines and proteases which are responsible for causing damage or disorder within body tissues leading towards improved health outcomes. However, few research studies have been conducted regarding this protein thus making it difficult for researchers determine its potential uses outside of cancer & tuberculosis treatment procedures globally.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of biopharmaceutical companies and bioscience research institutes involved in drug discovery process is one of the major factors responsible for its largest share. Moreover, increasing R&D activities by various pharmaceutical companies to develop novel drugs targeting CXCL8-expressing cancer cells is expected to drive this regional market over the forecast period.
Asia Pacific region is anticipated to grow at a lucrative rate during the forecast period owing to rising investments by various government organizations and private firms for developing advanced therapeutics against CXCL8-expressing cancers. For instance, Novartis AG has invested around USD X million for research on CXCR4 therapy which targets lung cancer stem cells that are resistant to treatment with currently available therapies such as chemotherapy or targeted therapy drugs such as PD-1 or CTLA-4 inhibitors (Opdivo and Imbruvica).
Growth Factors:
- Increasing prevalence of chronic diseases: The global prevalence of chronic diseases is increasing at an alarming rate. This is primarily because of the changing lifestyles and dietary habits of people across the world. Chronic diseases are characterized by long-term symptoms and require ongoing treatment. As a result, there is a growing demand for therapies that can effectively manage these conditions. CXCL8 has been shown to play an important role in the pathogenesis of several chronic diseases, including rheumatoid arthritis, asthma, and cancer. This is likely to drive demand for this protein in the coming years.
- Growing awareness about CXCL8's therapeutic potential: There is growing awareness among healthcare professionals about the therapeutic potential of CXCL8 proteins for managing various chronic diseases conditions. This is likely to lead to increased use of these proteins in clinical practice settings in the coming years.
Scope Of The Report
Report Attributes
Report Details
Report Title
CXCL8(Chemokine Protein) Market Research Report
By Type
Above 90%, Above 95%, Above 99%, Others
By Application
Biopharmaceutical Companies, Hospitals, Bioscience Research Institutions, Others
By Companies
Aviva Systems Biology Corporation(USA), Atlas Antibodies(Sweden), Abbexa Ltd(UK), Abiocode(US), Boster Biological Technology(USA), Biobyt(UK), Bio-Rad(US), Bioss Antibodies(US), Biosensis(US), BioLegend(US), BioVision(US), BethylLaboratories(US), Epigentek(US), EnzoLifeSciences(Switzerland), Genetex(US), Lifespan Biosciences(US), Novus Biologicals(US), Proteintech(US), ProSci(US), ProteoGenix(France), R&D Systems(US), Rockland(US), St John's Laboratory Ltd(UK), Stemcell(Canada), Thermo Fisher Scientific(US), USBiological(US)
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
231
Number of Tables & Figures
162
Customization Available
Yes, the report can be customized as per your need.
Global CXCL8(Chemokine Protein) Market Report Segments:
The global CXCL8(Chemokine Protein) market is segmented on the basis of:
Types
Above 90%, Above 95%, Above 99%, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Biopharmaceutical Companies, Hospitals, Bioscience Research Institutions, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Aviva Systems Biology Corporation(USA)
- Atlas Antibodies(Sweden)
- Abbexa Ltd(UK)
- Abiocode(US)
- Boster Biological Technology(USA)
- Biobyt(UK)
- Bio-Rad(US)
- Bioss Antibodies(US)
- Biosensis(US)
- BioLegend(US)
- BioVision(US)
- BethylLaboratories(US)
- Epigentek(US)
- EnzoLifeSciences(Switzerland)
- Genetex(US)
- Lifespan Biosciences(US)
- Novus Biologicals(US)
- Proteintech(US)
- ProSci(US)
- ProteoGenix(France)
- R&D Systems(US)
- Rockland(US)
- St John's Laboratory Ltd(UK)
- Stemcell(Canada)
- Thermo Fisher Scientific(US)
- USBiological(US)
 Market Overview.svg)
Highlights of The CXCL8(Chemokine Protein) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Above 90%
- Above 95%
- Above 99%
- Others
- By Application:
- Biopharmaceutical Companies
- Hospitals
- Bioscience Research Institutions
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the CXCL8(Chemokine Protein) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
CXCL8 is a chemokine protein that plays an important role in the inflammatory response.
Some of the key players operating in the cxcl8(chemokine protein) market are Aviva Systems Biology Corporation(USA), Atlas Antibodies(Sweden), Abbexa Ltd(UK), Abiocode(US), Boster Biological Technology(USA), Biobyt(UK), Bio-Rad(US), Bioss Antibodies(US), Biosensis(US), BioLegend(US), BioVision(US), BethylLaboratories(US), Epigentek(US), EnzoLifeSciences(Switzerland), Genetex(US), Lifespan Biosciences(US), Novus Biologicals(US), Proteintech(US), ProSci(US), ProteoGenix(France), R&D Systems(US), Rockland(US), St John's Laboratory Ltd(UK), Stemcell(Canada), Thermo Fisher Scientific(US), USBiological(US).
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. CXCL8(Chemokine Protein) Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. CXCL8(Chemokine Protein) Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. CXCL8(Chemokine Protein) Market - Supply Chain
4.5. Global CXCL8(Chemokine Protein) Market Forecast
4.5.1. CXCL8(Chemokine Protein) Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. CXCL8(Chemokine Protein) Market Size (000 Units) and Y-o-Y Growth
4.5.3. CXCL8(Chemokine Protein) Market Absolute $ Opportunity
5. Global CXCL8(Chemokine Protein) Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. CXCL8(Chemokine Protein) Market Size and Volume Forecast by Type
5.3.1. Above 90%
5.3.2. Above 95%
5.3.3. Above 99%
5.3.4. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global CXCL8(Chemokine Protein) Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. CXCL8(Chemokine Protein) Market Size and Volume Forecast by Application
6.3.1. Biopharmaceutical Companies
6.3.2. Hospitals
6.3.3. Bioscience Research Institutions
6.3.4. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global CXCL8(Chemokine Protein) Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. CXCL8(Chemokine Protein) Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global CXCL8(Chemokine Protein) Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. CXCL8(Chemokine Protein) Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global CXCL8(Chemokine Protein) Demand Share Forecast, 2019-2026
9. North America CXCL8(Chemokine Protein) Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America CXCL8(Chemokine Protein) Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America CXCL8(Chemokine Protein) Market Size and Volume Forecast by Application
9.4.1. Biopharmaceutical Companies
9.4.2. Hospitals
9.4.3. Bioscience Research Institutions
9.4.4. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America CXCL8(Chemokine Protein) Market Size and Volume Forecast by Type
9.7.1. Above 90%
9.7.2. Above 95%
9.7.3. Above 99%
9.7.4. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America CXCL8(Chemokine Protein) Demand Share Forecast, 2019-2026
10. Latin America CXCL8(Chemokine Protein) Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America CXCL8(Chemokine Protein) Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America CXCL8(Chemokine Protein) Market Size and Volume Forecast by Application
10.4.1. Biopharmaceutical Companies
10.4.2. Hospitals
10.4.3. Bioscience Research Institutions
10.4.4. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America CXCL8(Chemokine Protein) Market Size and Volume Forecast by Type
10.7.1. Above 90%
10.7.2. Above 95%
10.7.3. Above 99%
10.7.4. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America CXCL8(Chemokine Protein) Demand Share Forecast, 2019-2026
11. Europe CXCL8(Chemokine Protein) Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe CXCL8(Chemokine Protein) Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe CXCL8(Chemokine Protein) Market Size and Volume Forecast by Application
11.4.1. Biopharmaceutical Companies
11.4.2. Hospitals
11.4.3. Bioscience Research Institutions
11.4.4. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe CXCL8(Chemokine Protein) Market Size and Volume Forecast by Type
11.7.1. Above 90%
11.7.2. Above 95%
11.7.3. Above 99%
11.7.4. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9 Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe CXCL8(Chemokine Protein) Demand Share, 2019-2026
12. Asia Pacific CXCL8(Chemokine Protein) Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific CXCL8(Chemokine Protein) Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific CXCL8(Chemokine Protein) Market Size and Volume Forecast by Application
12.4.1. Biopharmaceutical Companies
12.4.2. Hospitals
12.4.3. Bioscience Research Institutions
12.4.4. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific CXCL8(Chemokine Protein) Market Size and Volume Forecast by Type
12.7.1. Above 90%
12.7.2. Above 95%
12.7.3. Above 99%
12.7.4. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific CXCL8(Chemokine Protein) Demand Share, 2019-2026
13. Middle East & Africa CXCL8(Chemokine Protein) Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa CXCL8(Chemokine Protein) Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa CXCL8(Chemokine Protein) Market Size and Volume Forecast by Application
13.4.1. Biopharmaceutical Companies
13.4.2. Hospitals
13.4.3. Bioscience Research Institutions
13.4.4. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa CXCL8(Chemokine Protein) Market Size and Volume Forecast by Type
13.7.1. Above 90%
13.7.2. Above 95%
13.7.3. Above 99%
13.7.4. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa CXCL8(Chemokine Protein) Demand Share, 2019-2026
14. Competition Landscape
14.1. Global CXCL8(Chemokine Protein) Market: Market Share Analysis
14.2. CXCL8(Chemokine Protein) Distributors and Customers
14.3. CXCL8(Chemokine Protein) Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Aviva Systems Biology Corporation(USA)
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Atlas Antibodies(Sweden)
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Abbexa Ltd(UK)
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Abiocode(US)
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Boster Biological Technology(USA)
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Biobyt(UK)
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Bio-Rad(US)
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Bioss Antibodies(US)
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Biosensis(US)
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. BioLegend(US)
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. BioVision(US)
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. BethylLaboratories(US)
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Epigentek(US)
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. EnzoLifeSciences(Switzerland)
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. Genetex(US)
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. Lifespan Biosciences(US)
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. Novus Biologicals(US)
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. Proteintech(US)
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. ProSci(US)
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. ProteoGenix(France)
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
